K210093 is an FDA 510(k) clearance for the AccuFFRangio. This device is classified as a X-ray Angiographic Imaging Based Coronary Vascular Simulation Software Device (Class II - Special Controls, product code QHA).
Submitted by ArteryFlow Technology Co., Ltd. (Hangzhou City, CN). The FDA issued a Cleared decision on September 10, 2021, 239 days after receiving the submission on January 14, 2021.
This device falls under the Radiology FDA review panel. Regulated under 21 CFR 892.1600. X-ray Angiographic Imaging Based Coronary Vascular Simulation Software Device Is A Prescription Device That Provides An Image Analysis Tool To Assess Blood Flow In The Coronary Vascular System Using X-ray Angiographic Imaging Data. X-ray Angiographic Imaging Based Coronary Vascular Simulation Software Device Solves Algorithms And Yields Simulation-based Metrics For Certain Cardiology Applications. X-ray Angiographic Imaging Based Coronary Vascular Simulation Software Device Cannot Be Used Alone For Clinical Decision Making And Clinical Management, And Is A Tool Intended To Generate Results For Use And Review By A Qualified Clinician..